Kingmed's 1H26 preliminary net profit exceeded expectations; Goldman Sachs maintains Buy rating

Overview

This report is Goldman Sachs' earnings review of Kingmed (603882.SS). The company released its 1H26 preliminary results on July 13, 2026, reporting net profit of Rmb170mn-220mn, above Goldman Sachs' forecast of Rmb156mn; it also announced its 2026 equity incentive plan. Based on this, Goldman Sachs raised or adjusted its 2026-2028 earnings forecasts and maintained its Buy rating.

Core views

Goldman Sachs' core view is that Kingmed, as a leading player in China's ICL industry, faces challenges from DRG/DIP reform, weak high-end testing demand, pricing pressure, and accounts receivable risk, but industry supply-side clearing and tighter compliance are easing competition. The company can support earnings stabilization and approach an inflection point through cost and expense control, digital transformation, laboratory network expansion, rising outsourcing penetration, and market share gains from industry consolidation.

Analysis framework

The report analyzes the company's 1H26 preliminary results, 2026 equity incentive targets, policy impact assessment, industry competitive landscape, margin recovery trends, and valuation methodology. The valuation uses a five-year exit P/E method and references P/E levels of global comparable companies.

Methodology notes

• Valuation methodsFive-year exit P/E method

  Estimating the target price based on future earnings and the exit P/E multiple

  Goldman Sachs' 12-month target price of Rmb36 for Kingmed is based on a five-year exit P/E method, using a 9.5% discount rate and referencing a 21.8x P/E for global peers.

• Factor analysisGS Factor Profile

  Comparing growth, financial returns, valuation multiples, and composite factors

  Goldman Sachs' factor profile compares the stock with the covered market and industry peers across growth, financial returns, valuation multiples, and composite indicators to help assess its investment characteristics.

• M&A assessmentM&A Rank

  Scoring the probability of becoming an M&A target

  Goldman Sachs uses an M&A rank from 1 to 3 to assess the probability of a company becoming an acquisition target; the report notes that this framework is a general methodology for globally covered stocks.

• Database toolQuantum

  Database of financial history, forecasts, and ratios

  Quantum is Goldman Sachs' proprietary database, used for in-depth single-company analysis and cross-industry and cross-market company comparisons.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 603882.SS

  Covered company; leading player in China's ICL industry

  Strengths

  1H26 preliminary net profit exceeded expectations; cost control and digital transformation improved operating efficiency; industry supply-side clearing supports market share gains; valuation remains reasonable relative to the recovery outlook.

  Weaknesses

  Short-term weakness in high-end testing demand; policy reforms may affect testing volumes and prices; accounts receivable collection remains a key investor concern.

  Comparison

  Goldman Sachs compares it on a relative-rating basis with healthcare companies in its covered universe, including Aier Eye Hospital, Dian Diagnostics, Mindray, and United Imaging.

  Risks

  Industry outsourcing demand recovers more slowly than expected, high-end testing demand remains weak, pricing pressure intensifies under VBP and local procurement policies, and industry consolidation progresses more slowly than expected.

Key data

• 1H26 preliminary net profitRmb170mn-220mnCompany-disclosed range, above Goldman Sachs' forecast of Rmb156mn; 1H25 recorded a net loss of Rmb85mn.
• 2026/2027/2028 revenue vesting targetsAt least 6%/14.5%/26% growth versus 2025Equivalent to approximately 6%/8%/10% annual revenue growth.
• Non-GAAP net profit targetsRmb390mn/Rmb500mn/Rmb600mnTargets for 2026/2027/2028 under the equity incentive plan.
• 12-month target priceRmb36Goldman Sachs maintains its Buy rating, implying approximately 39.4% upside from the current price of Rmb25.82.
• Valuation parameters9.5% discount rate; global peers' P/E 21.8xUsed for the five-year exit P/E valuation method.

Impact & implications

The report suggests that Kingmed's investment thesis is shifting from post-pandemic margin compression and accounts receivable concerns toward earnings recovery, improved operating efficiency, and rising industry concentration. If the equity incentive targets are achieved, market confidence in the stability of the company's earnings may strengthen.

Risks

• Industry outsourcing demand recovers more slowly than expected.
• High-end testing demand remains weak.
• Pricing pressure intensifies under VBP and local procurement policies.
• Industry consolidation and market share gains progress more slowly than expected.
• DRG 3.0 and nationwide standardization of healthcare service prices may suppress testing volumes or prices.
• Accounts receivable collection falls short of expectations.

What to watch

• The pace of industry consolidation and Kingmed's market share gains.
• The path of margin recovery and the effectiveness of cost control.
• Progress in accounts receivable collection.
• The actual impact of DRG/DIP reform and healthcare service price standardization on testing volumes and prices.
• Achievement of the equity incentive plan's revenue and non-GAAP net profit targets.